NovaGo Therapeutics has closed a $30.0M Series B round, with backing from Neurimmune AG and Pureos Bioventures.
The company is developing fully human monoclonal antibodies designed to block Nogo-A, a protein that inhibits both vascular and nerve growth in the central nervous system. By targeting this pathway, NovaGo鈥檚 candidates aim to offer a safer, more effective treatment option for CNS indications-an area where few therapies have managed to move the needle. The fresh capital arrives as the biotech looks to push its lead programs forward, though specifics on clinical timelines were not disclosed.

















